View Clinical Trial (Medical Research Study)

Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects - NCT00735449-(Clinical Trial 236656)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Newark
State:  
NJ
Zip Code:
Conditions: Glaucoma - Ocular Hypertension
Purpose: Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive therapy to Xalatan in subjects with glaucoma or ocular hypertension.
Study summary:
Criteria: Inclusion Criteria: - Be at least 18 years of age - Give written informed consent - Be in good general health as determined by your doctor - Have a diagnosis of unilateral or bilateral glaucoma or ocular hypertension - If you are a female of child bearing potential, you must be willing to practice effective contraception for the duration of the study (i.e., abstinence, spermicide, condoms, or birth control pills) - Understand the study instructions, and be able to follow the study instructions; and - Be likely to complete the entire study period (12 weeks), including all regularly scheduled study visits Exclusion Criteria: - Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study interpretation - History of severe renal or hepatic impairment - Subjects with severe cardiovascular disease should not be enrolled unless their disease is controlled and clearance has been obtained from the subject's primary care physician and/or cardiologist - Contraindications to beta-andrenoceptor antagonist therapy such as chronic obstructive pulmonary disease, bronchial asthma, sinus bradycardia, second and third degree atrioventricular block, overt cardiac failure and cardiogenic shock or uncontrolled congestive heart failure - Any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results; and - Concurrent participation or prior participation in any investigational drug or device study within the last 30 days prior to the screening visit
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: February 17, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.